secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-123990
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma reports positive Phase 3 setmelanotide data in young children; files for EU approval
--------------------------------------------------------------------------------

- Phase 3 pediatrics trial: 83.3% (10/12) achieved BMI-Z score reduction ≥0.2 at 52 weeks; mean BMI reduction 18.4%.
- Submitted Type II variation to EMA for setmelanotide in children 2 to <6 with BBS/POMC/PCSK1/LEPR deficiency; sNDA to FDA planned H1 2024.
- Phase 2 DAYBREAK trial: response rates by genotype ranged 25%–56.3%; 49 patients randomized into Stage 2 placebo-controlled withdrawal; data expected H2 2024.
- IND submitted for RM-718 (weekly MC4R agonist); Phase 1 trials including hypothalamic obesity planned H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923123990/0001104659-23-123990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923123990/tm2332304d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer